Agendia Gains $23M

Huntington Beach-based Agendia, a developer of molecular cancer diagnostics, said today that it has raised $23M in a Series E financing round. The firm said the funding came from an undisclosed, family investment firm, as well as existing investors. Agendia develops diagnostic assays for determining the probability of metastasis, to help physicians determine if chemotherapy is necessary. The firm said the funding will go to accelerate commercialization of its products in the U.S. market. Agendia also has operations in Amsterdam, The Netherlands. More information »